Health Professionals

Researchers have developed an innovative nano-immune agonist that significantly improves immunotherapy outcomes for melanoma—a highly aggressive and hard-to-treat form of skin cancer.

Among patients with advanced melanoma treated with ipilimumab (Yervoy) and nivolumab (Opdivo), decreasing values of circulating tumor DNA (ctDNA) in tumor-informed liquid biopsies during the first 6 weeks of therapy were associated with improved survival outcomes, a recent study showed.

Melanoma in adolescents and young adults (AYAs) has distinct epidemiologic characteristics, with a declining incidence over the past 2 decades but an increasing trend in all-cause and cancer-specific mortality among specific populations, according to study results published in Clinics in Dermatology.

Men with melanoma tend to be diagnosed later and have worse outcomes. Artificial intelligence can help change that, a review suggests.